

**REAL LIFE EXPERIENCE OF MEDICAL CANNABIS TREATMENT IN AUTISM:
ANALYSIS OF SAFETY AND EFFICACY.**

Lihl Bar-Lev Schleider MA^{1,2}, Raphael Mechoulam PhD³, Naama Saban², Gal Meiri MD
MHA^{4,5}, *Victor Novack MD PhD¹.

¹ Clinical Cannabis Research Institute, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel.

² Research Department, Tikun Olam LTD.


³ Institute for Drug Research, School of Pharmacy, the Hebrew University of Jerusalem, Israel.

⁴ Negev Autism Centre, Ben-Gurion University of the Negev, Beer Sheva, Israel

⁵ Soroka University Medical and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

Corresponding author – Victor Novack - VictorNo@clalit.org.il

Supplementary figure S1: Distribution of cannabinoids consumptions. Total CBD (in mg) consumed at every intake by 66 patients receiving oil with 30% CBD and 1.5% THC. THC is 1/20 of the amount of CBD.



Supplementary figure S2: Quality of life assessment. Quality of life was assessed prior to and six months after initiation of cannabis treatment. $p < 0.001$

